Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Exploratory analysis of AML patients with TP53 mutations showed a median OS of 66.9 months compared to 93 months in AML patients without TP53 mutation, and median EFS of 11.4 months compared to 17.1 months in patients without TP53 mutation; however, these differences did not reach statistical significance (Supplementary Fig. 7).

also in 111,027 other papers